NCT00051909

Brief Summary

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Nov 2002

Shorter than P25 for phase_2

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2002

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 17, 2003

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 20, 2003

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2003

Completed
Last Updated

July 19, 2006

Status Verified

July 1, 2006

First QC Date

January 17, 2003

Last Update Submit

July 18, 2006

Conditions

Alzheimer's Disease

Keywords

Alzheimer's Disease

Interventions

LY451395DRUG

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must have a clinical diagnosis of Alzheimer's Disease
  • Must be at least 50 years of age
  • Must fluently read and speak English
  • Must have a reliable caregiver

You may not qualify if:

  • Has serious health problems other than Alzheimer's Disease
  • Cannot swallow whole pills
  • Has had a menstrual period in the last two years
  • Takes insulin for diabetes
  • Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Unknown Facility

Beverly Hills, California, United States

Location

Unknown Facility

Fresno, California, United States

Location

Unknown Facility

Boca Raton, Florida, United States

Location

Unknown Facility

Fort Lauderdale, Florida, United States

Location

Unknown Facility

Miami Beach, Florida, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Tulsa, Oklahoma, United States

Location

Unknown Facility

Wichita Falls, Texas, United States

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

N-((2-(4'-(2-(methylsulfonyl)amino)ethyl)(1,1'-biphenyl)-4-yl)propyl)-2-propanesulfonamide

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 17, 2003

First Posted

January 20, 2003

Study Start

November 1, 2002

Study Completion

June 1, 2003

Last Updated

July 19, 2006

Record last verified: 2006-07

Locations

US(9)